Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus etoposide maintenance therapy in extensive-stage small-cell lung cancer after failure of second-line chemotherapy
ChiCTR-OIC-17012887Phase 2Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Nov 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and etoposide in small cell lung cancer (SCLC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Progression-free survival. Started Nov 2017; status: recruiting.
02
Drugs
Rivoceranibetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-OIC-17012887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17012887.